Significantly fewer women screened with HPV testing alone had high-grade pathologies four years later compared to those receiving cytology testing.
IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
One outcome of a recent FDA workshop about the potential for using self-collection for Pap testing was that it might be better to do self-collection in combination with molecular testing.
The firm has launched a multiplex real-time PCR assay that detects HPV 16, HPV 18, and a pool of 12 other high-risk HPV subtypes.
The acquisition of the Netherlands-based lab follows an acquisition of a Belgian clinical lab earlier this month.
The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.